ACE and diabetic kidney disease: Rossing et al. reported that the addition of spironolactone to an existing ACE inhibitor or ARB antihypertensive therapy reduced SBP/DBP by 10/5 mmHg versus a placebo in a study of 21 patients with diabetic nephropathy [28].